GlassScriptPhysician profile
Lauren Bledsoe
NPI 1861128258
$1,454.90
in general payments reported to CMS, 2019-2025
14 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $149 · 2023: $805 · 2024: $221 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $574.03 | 2023-2025 | |
| Glaxosmithkline, LLC. | $178.24 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $112.13 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $106.10 | 2022 | |
| Lilly USA, LLC | $99.06 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $88.34 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Organon LLC | $71.43 | 2023-2024 | Nexplanon |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.06 | 2025 | Caplyta |
| Exact Sciences Corporation | $52.24 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $35.15 | 2025 | Rybelsus, Ozempic, Wegovy |
| Radius Health, INC. | $21.93 | 2023 | Tymlos |
| Merck Sharp & Dohme LLC | $21.16 | 2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Dexcom, INC. | $15.62 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $15.41 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Bledsoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.